The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
The hypothesis for this study is that the GLP-1Ra Semaglutide has a positive effect on the
balance between build-up and degradation as well as the strength of the bones in men and
women aged 40-85 years at increased risk of bone fractures. Treatment involves injection of
Semaglutide 1.34 mg/ml once a week or corresponding volume of placebo once a week for 52
weeks. The effect will be measured by bone markers in blood samples, bone scans, bone tissue
tests (bone biopsy), and direct bone strength measured by microindentation at the start and
end of the study.